Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 10, 2016 07:30 ET | Source: Idera Pharmaceuticals, Inc.

Idera to Present at the Stifel 2016 Healthcare Conference

CAMBRIDGE, Mass. and EXTON, Pa., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
November 09, 2016 07:30 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals to Provide Multiple Presentations on Intratumoral IMO-2125 at the 2016 Society for Immunotherapy of Cancer (SITC) Annual Meeting

CAMBRIDGE, Mass. and EXTON, Pa., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
October 28, 2016 07:30 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Reports Third Quarter 2016 Financial Results

CAMBRIDGE, Mass. and EXTON, Pa., Oct. 28, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and...
October 07, 2016 09:04 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass. and EXTON, Pa., Oct. 07, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) (“Idera” or the “Company”) today announced the pricing of an underwritten public offering...
October 05, 2016 16:00 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass. and EXTON, Pa., Oct. 05, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) (“Idera” or the “Company”) today announced that it intends to offer and sell up to...
September 27, 2016 07:30 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Presents New Third Generation Antisense (3GA) Data at the 12th Annual Meeting of the Oligonucleotide Therapeutics Society

CAMBRIDGE, Mass. and EXTON, Pa., Sept. 27, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and...
September 27, 2016 03:23 ET | Source: Idera Pharmaceuticals, Inc.

아이데라제약, 임상1상 복용량 증가 시험에서 고무적 결과 발표…PD-1 치료 실패한 전이성 흑색종 환자 대상으로 종양내 IMO-2125 이필리무맵 함께 투여

-PD-1 치료 실패한 피부 흑색종 환자 3명 중 1명, 완전반응(CR) 보여-IMO-2125 임상개발 우선 추진 위해 B세포 림프종 위한 IMO-8400 개발 보류미국 매사추세츠주 캠브리지 / 펜실베이니아주 엑스턴, Sept. 27, 2016 (GLOBE NEWSWIRE) -- 아이데라제약(Idera Pharmaceuticals, Inc.) (나스닥...
September 27, 2016 03:23 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals宣布针对PD-1难治型黑色素瘤患者所进行的肿瘤内IMO-2125及Ipilimumab结合疗法1期剂量递增临床试验取得理想结果

– 3位PD-1难治型黑色素瘤患者病情有所缓解，其中1位患者已完全有效 –– 为重点专注于IMO-2125的临床开发，公司暂停开发B细胞淋巴癌治疗药物IMO-8400 –麻萨诸塞州剑桥及宾夕法尼亚州埃克斯顿, Sept. 27, 2016 (GLOBE NEWSWIRE) --...
September 27, 2016 03:23 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals宣佈針對PD-1難治型黑色素瘤患者所進行的腫瘤內IMO-2125及Ipilimumab結合療法1期劑量遞增臨床試驗取得理想結果

– 3位PD-1難治型黑色素瘤患者病情有所緩解，其中1位患者已完全有效 – – 為重點專注於IMO-2125的臨床開發，公司暫停開發B細胞淋巴癌治療藥物IMO-8400 – 麻薩諸塞州劍橋及賓夕法尼亞州埃克斯頓, Sept. 27, 2016 (GLOBE NEWSWIRE) --...
September 26, 2016 19:23 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals comunica dados promissores do escalonamento de dose de Fase 1 em teste clínico de IMO-2125 intratumoral combinado com ipilimumab em pacientes com melanoma metastático refratário PD-1

- 3 pacientes com melanoma cutâneo refratário PD-1 são respondentes, incluindo uma resposta completa (CR) –- Estimulada pela crescente priorização do desenvolvimento clínico de IMO-2125, a empresa...